{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:40:48Z","timestamp":1788435648728,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100024217","name":"Osaka International Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the in vitro drug sensitivity of patient-derived cancer organoids (PDCOs) established from residual samples from saline flushes (RSSF) collected during routine endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in patients with pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Organoids were cultured under mutation-selective conditions. IC\n                      <jats:sub>50<\/jats:sub>\n                      values for 5-fluorouracil (5-FU), SN-38, oxaliplatin, gemcitabine, and paclitaxel were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PDCOs showed variable responses to the drugs. Exploratory quantitative analysis using ordinal sensitivity scoring and ROC curves (Area under the curve [AUC] up to 0.917) indicated that lower in vitro IC\u2085\u2080 scores tended to associate with clinical responders (PR\/uPR) compared with non-responders (progressive or stable disease [PD\/SD]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated the feasibility and potential usefulness of in vitro drug sensitivity profiling of pancreatic cancer using RSSF-derived PDCOs. These findings represent the first step toward clinical application, and further validation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04111-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T07:05:25Z","timestamp":1763708725000},"page":"1940-1946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routine EUS-FNA"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4222-4736","authenticated-orcid":false,"given":"Tomoya","family":"Ekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mizote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisataka","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"4111_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030562","volume":"11","author":"J Ushio","year":"2021","unstructured":"Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, et al. Pancreatic ductal adenocarcinoma: epidemiology and risk factors. Diagnostics. 2021;11:562. https:\/\/doi.org\/10.3390\/diagnostics11030562.","journal-title":"Diagnostics"},{"key":"4111_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030525","volume":"14","author":"L M\u00e4kinen","year":"2022","unstructured":"M\u00e4kinen L, V\u00e4h\u00e4-Koskela M, Juusola M, Mustonen H, Wennerberg K, Hagstr\u00f6m J, et al. Pancreatic cancer organoids in the field of precision medicine: a review of literature and experience on drug sensitivity testing with multiple readouts and synergy scoring. Cancers (Basel). 2022;14:525. https:\/\/doi.org\/10.3390\/cancers14030525.","journal-title":"Cancers (Basel)"},{"key":"4111_CR3","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1055\/a-1713-3404","volume":"10","author":"K Ikezawa","year":"2022","unstructured":"Ikezawa K, Ekawa T, Hasegawa S, Kai Y, Takada R, Yamai T, et al. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Endosc Int Open. 2022;10:E82\u20137. https:\/\/doi.org\/10.1055\/a-1713-3404.","journal-title":"Endosc Int Open"},{"key":"4111_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jmoldx.2022.01.008","volume":"24","author":"B Wei","year":"2022","unstructured":"Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L, et al. Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden and clinical utility for predicting response to pembrolizumab. J Mol Diagn. 2022;24:600\u20138. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.01.008.","journal-title":"J Mol Diagn"},{"key":"4111_CR5","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-018-07644-6","volume":"9","author":"A Kazi","year":"2018","unstructured":"Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RHY, et al. GSK3 suppression upregulates \u03b2-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun. 2018;9:5154. https:\/\/doi.org\/10.1038\/s41467-018-07644-6.","journal-title":"Nat Commun"},{"key":"4111_CR6","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","volume":"116","author":"E Driehuis","year":"2019","unstructured":"Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A. 2019;116:26580\u201390. https:\/\/doi.org\/10.1073\/pnas.1911273116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4111_CR7","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/0008-5472.CAN-20-4026","volume":"81","author":"M Gr\u00f6nholm","year":"2021","unstructured":"Gr\u00f6nholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Cancer Res. 2021;81:3149\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4026.","journal-title":"Cancer Res"},{"key":"4111_CR8","doi-asserted-by":"publisher","unstructured":"Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, et al. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: efficient identification of cancer genome alterations in advanced pancreatic cancer. Ann Oncol. 2018;29 Suppl 8:viii216\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdy282.028","DOI":"10.1093\/annonc\/mdy282.028"},{"key":"4111_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/den.14120","volume":"34","author":"M Kitano","year":"2022","unstructured":"Kitano M, Minaga K, Hatamaru K, Ashida R. Clinical dilemma of endoscopic ultrasound-guided fine needle aspiration for resectable pancreatic body and tail cancer. Dig Endosc. 2022;34:307\u201316. https:\/\/doi.org\/10.1111\/den.14120.","journal-title":"Dig Endosc"},{"key":"4111_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174151","volume":"12","author":"T Tashiro","year":"2017","unstructured":"Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, et al. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS ONE. 2017;12:e0174151. https:\/\/doi.org\/10.1371\/journal.pone.0174151.","journal-title":"PLoS ONE"},{"key":"4111_CR11","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1080\/07853890.2022.2122550","volume":"54","author":"D Shu","year":"2022","unstructured":"Shu D, Shen M, Li K, Han X, Li H, Tan Z, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. Ann Med. 2022;54:2581\u201397. https:\/\/doi.org\/10.1080\/07853890.2022.2122550.","journal-title":"Ann Med"},{"key":"4111_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8:1112\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0349.","journal-title":"Cancer Discov"},{"key":"4111_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920\u20136. https:\/\/doi.org\/10.1126\/science.aao2774.","journal-title":"Science"},{"key":"4111_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1476-4598-8-125","volume":"8","author":"W Huanwen","year":"2009","unstructured":"Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer. 2009;8:125. https:\/\/doi.org\/10.1186\/1476-4598-8-125.","journal-title":"Mol Cancer"},{"key":"4111_CR15","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1093\/carcin\/bgt227","volume":"34","author":"N Awasthi","year":"2013","unstructured":"Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, et al. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis. 2013;34:2361\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgt227.","journal-title":"Carcinogenesis"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04111-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:53:06Z","timestamp":1776765186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04111-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4111"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04111-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Osaka International Cancer Institute (approval no. OICI 18118).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants in accordance with the ethical guidelines and data protection regulations of the Osaka International Cancer Institute to ensure anonymity and confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}